CohBar’s treatment of idiopathic pulmonary fibrosis, or IPF, was granted orphan status by the FDA, according to a post to the agency’s website. Reference Link
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CWBR: